Early Life and Scientific Education
Stanley Norman Cohen was born on November 17, 1922, in Brooklyn, New York, to Jewish immigrant parents. He grew up during the Great Depression, an experience that fostered a disciplined work ethic. Cohen attended the City College of New York (CCNY), earning a Bachelor of Science in Chemistry in 1943. After serving in the U.S. Army Air Forces during World War II, he returned to academia, enrolling in the graduate program at the University of Michigan, where he received his Ph.D. in Biochemistry in 1949 under the mentorship of Dr. Rudi Alexander, a pioneer in protein chemistry.
Following his doctorate, Cohen completed a post‑doctoral fellowship at the University of Pennsylvania, working in the laboratory of Dr. Horace Judson on protein synthesis. This period honed his expertise in biochemical techniques that later proved essential for his groundbreaking work on growth factors.
Entry Into Biomedical Research
In 1956, Cohen joined the faculty of the College of Physicians and Surgeons at Columbia University as an assistant professor of biochemistry. His early research focused on the metabolism of amino acids, but a pivotal moment arrived in 1962 when he began collaborating with neurobiologist Dr. Rita Levi‑Montalcini, who was investigating nerve growth factor (NGF). Their complementary expertise led them to explore whether similar growth‑promoting molecules existed outside the nervous system.
Major Work and Career Milestones
While at Columbia, Cohen and Levi‑Montalcini isolated a protein from mouse submaxillary glands that accelerated the growth of epidermal cells in vitro. They named this protein epidermal growth factor (EGF). In a series of seminal papers published between 1964 and 1966 in the Journal of Biological Chemistry and Nature, they demonstrated that EGF could bind to a specific cell‑surface receptor, initiating a cascade of intracellular events that regulate cell division and differentiation.
The discovery of EGF opened a new field—growth‑factor biology—and provided a molecular framework for understanding how cells communicate during development, wound healing, and tumorigenesis. In 1979, Cohen identified the epidermal growth factor receptor (EGFR) and showed that it possessed intrinsic tyrosine kinase activity, a finding that later underpinned the development of targeted cancer therapies such as trastuzumab and erlotinib.
For these contributions, Cohen, together with Levi‑Montalcini, received the 1986 Nobel Prize in Physiology or Medicine. The Nobel Committee highlighted their work as “the discovery of growth factors and their receptors, which have revolutionized our understanding of cell biology and disease.”
Beyond EGF, Cohen’s laboratory at Columbia (and later at Washington University in St. Louis, where he moved in 1970 as the William H. Fleming Professor of Biology) explored other signaling molecules, including transforming growth factor‑α (TGF‑α). His research group generated the first recombinant EGF, enabling large‑scale studies and therapeutic applications.
Specialty, Methods, and Professional Style
Cohen’s primary specialty was molecular biochemistry with a focus on signal transduction pathways that regulate cell growth. He was renowned for meticulous experimental design, employing biophysical methods such as ligand‑binding assays, chromatography, and later, molecular cloning techniques. Cohen emphasized collaboration across disciplines, routinely integrating neurobiology, developmental biology, and clinical oncology to translate basic discoveries into medical relevance.
In the classroom, Cohen was described as an exacting yet supportive mentor. He supervised over 80 Ph.D. candidates and post‑doctoral fellows, many of whom became leaders in academia and biotech. His teaching style emphasized critical thinking, reproducibility, and ethical rigor—a reflection of his belief that scientific progress must be grounded in transparent methodology.
Reception, Awards, and Controversies
Cohen’s work received broad acclaim. In addition to the Nobel Prize, he was elected to the National Academy of Sciences (1974), the American Academy of Arts and Sciences (1975), and received the Lasker Award for Basic Medical Research (1981). He was also honored with the Wolf Prize in Medicine (1991) and the National Medal of Science (1995).
While Cohen’s scientific record is largely uncontested, debates have arisen regarding the commercialization of growth‑factor research. Some critics argued that patents on recombinant EGF and related technologies created barriers for early‑stage academic investigators. Cohen, however, consistently advocated for open scientific exchange and publicly supported policies that balanced intellectual property with public health needs.
Legacy and Medical Impact
Stanley Cohen’s discovery of EGF and its receptor transformed multiple medical fields. In oncology, aberrations in EGFR signaling are now recognized as drivers of many cancers, guiding the development of targeted therapies that have extended patient survival. In dermatology, recombinant EGF formulations are employed to accelerate wound healing and treat skin disorders. Moreover, the conceptual framework of ligand‑receptor signaling pioneered by Cohen underlies modern therapeutics ranging from monoclonal antibodies to small‑molecule kinase inhibitors.
Beyond his research, Cohen’s legacy includes a generation of scientists trained under his mentorship, the establishment of the Cohen–Levi Montalcini Fund for research fellowships, and the ongoing relevance of his publications, which continue to be cited in contemporary literature on cell signaling. His career exemplifies how fundamental biochemical research can translate into tangible clinical advances.
